lnu.sePublications
Change search
CiteExportLink to record
Permanent link

Direct link
Cite
Citation style
  • apa
  • ieee
  • modern-language-association-8th-edition
  • vancouver
  • Other style
More styles
Language
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Other locale
More languages
Output format
  • html
  • text
  • asciidoc
  • rtf
Mannose-Binding Lectin is Associated with Thrombosis and Coagulopathy in Critically Ill COVID-19 Patients
Uppsala University, Sweden.
Uppsala University, Sweden.ORCID iD: 0000-0003-4675-1099
Uppsala University, Sweden.
Uppsala University, Sweden.
Show others and affiliations
2020 (English)In: Thrombosis and Haemostasis, ISSN 0340-6245, E-ISSN 2567-689X, E-ISSN 2567-689X, Vol. 120, no 12, p. 1720-1724Article in journal, Letter (Refereed) Published
Abstract [en]

The ongoing COVID-19 pandemic has caused significant morbidity and mortality worldwide, as well as profound effects on society. COVID-19 patients have an increased risk of thromboembolic (TE) complications, which develop despite pharmacological thromboprophylaxis. The mechanism behind COVID-19-associated coagulopathy remains unclear. Mannose-binding lectin (MBL), a pattern recognition molecule that initiates the lectin pathway of complement activation, has been suggested as a potential amplifier of blood coagulation during thromboinflammation. Here we describe data from a cohort of critically ill COVID-19 patients ( n =65) treated at a tertiary hospital center intensive care unit (ICU). A subset of patients had strongly elevated MBL plasma levels, and activity upon ICU admission, and patients who developed symptomatic TE (14%) had significantly higher MBL levels than patients without TE. MBL was strongly correlated to plasma D-dimer levels, a marker of COVID-19 coagulopathy, but showed no relationship to degree of inflammation or other organ dysfunction. In conclusion, we have identified complement activation through the MBL pathway as a novel amplification mechanism that contributes to pathological thrombosis in critically ill COVID-19 patients. Pharmacological targeting of the MBL pathway could be a novel treatment option for thrombosis in COVID-19. Laboratory testing of MBL levels could be of value for identifying COVID-19 patients at risk for TE events.

Place, publisher, year, edition, pages
Georg Thieme Verlag KG, 2020. Vol. 120, no 12, p. 1720-1724
Keywords [en]
thrombosis, COVID-19, complement system, mannose-binding lectin
National Category
Cell and Molecular Biology Immunology
Research subject
Biomedical Sciences, Immunology
Identifiers
URN: urn:nbn:se:lnu:diva-98340DOI: 10.1055/s-0040-1715835ISI: 000567116300001PubMedID: 32871607Scopus ID: 2-s2.0-85090968505Local ID: 2020OAI: oai:DiVA.org:lnu-98340DiVA, id: diva2:1473737
Available from: 2020-10-07 Created: 2020-10-07 Last updated: 2023-08-28Bibliographically approved

Open Access in DiVA

No full text in DiVA

Other links

Publisher's full textPubMedScopus

Authority records

Nilsson Ekdahl, Kristina

Search in DiVA

By author/editor
Hultström, MichaelNilsson Ekdahl, Kristina
By organisation
Department of Chemistry and Biomedical Sciences
In the same journal
Thrombosis and Haemostasis
Cell and Molecular BiologyImmunology

Search outside of DiVA

GoogleGoogle Scholar

doi
pubmed
urn-nbn

Altmetric score

doi
pubmed
urn-nbn
Total: 109 hits
CiteExportLink to record
Permanent link

Direct link
Cite
Citation style
  • apa
  • ieee
  • modern-language-association-8th-edition
  • vancouver
  • Other style
More styles
Language
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Other locale
More languages
Output format
  • html
  • text
  • asciidoc
  • rtf